Metabolic consequences of policystic ovarian syndrome;Skutki metaboliczne zespołu policystycznych jajników

Diabetologia Polska

Volumn 10, Issue 3, 2003, Pages 346-352

  Staszewicz, Pawel ^a,b   Kos Kudła, Beata ^a   Strzelczyk, Janusz ^a   Nasiek, Maja ^a  

^a AM   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Insulin resistance; Metabolic disorder; Policystic ovarian syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN;

ANOVULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIET; EARLY DIAGNOSIS; ENDOCRINE DISEASE; EXERCISE; HIRSUTISM; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MENSTRUATION DISORDER; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; REVIEW; SYMPTOM; TREATMENT INDICATION; WEIGHT REDUCTION;

EID: 0347360500     PISSN: 12334723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Zawadzki J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. W: Dunaif A., Givens J.R., Haseltine F., Meriam G.R. Polycystic ovary syndrome. Boston (MA): Blackwell Scientific Publications., 1992, 384.
2. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome. Mechanism and Implication for Pathogenesis. Endocr. Rev., 1997, 18, 774-800.
3. Adams J., Poison D.W., Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ, 1986, 293, 355-9.
4. Hull M.G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol. Endocrinol., 1987, 1, 235-45.
5. Cooper H., Spellacy W., Prem K. i wsp. Hereditary factors in the Stein-Leventhal syndrome. Am. J. Obstet. Gynecol., 1968, 100, 371-387.
6. Carey A.H., Chan K.L., Short F. i wsp. Evidence for a single gene effect in polycystic ovaries and male pattern baldness. Clin. Endocrinol., 1993, 38, 653-658.
7. Govind A., Obhrai M.S., Clayton R.N. Polycystic Ovaries Are Inherited as an Autosomal Dominant Trait: Analysis of 29 Polycystic Ovary Syndrome and 10 Control Families. J. Clin. Endocrinol. Metab., 1999, 84, 38-44.
8. Legro R.S., Driscoll D., Strauss J.F. i wsp. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. USA., 1998, 95, 14956-14960.
9. Lewy V.D., Danadian K., Witchel S.F. i wsp. Early metabolic abnormalities in girls with polycystic ovarian syndrome. J. Pediatr., 2001, 138, 38-44.
10. Franks S., Gharani N., Waterworth D. i wsp. Genetics of polycystic ovary syndrome. Mol. Cel. Endocrinol., 1998, 145, 123-128.
11. Waterworth D.M., Bennett S.T., Gharani N. i wsp. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet, 1997, 349, 986-990.
12. Gharani N., Waterworth D.M., Batty S. i wsp. Association of the steroid synthesis gene CYP1 la with polycystic ovary syndrome and hyperandrogenism. Hum. Mol. Genet., 1997, 6, 397-402.
13. Rosenfeld R. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol. Metab. Clin. North. Am., 1999, 28, 265.
14. Yen S. The polycystic ovary syndrome. Clin. Endocrinol., 1980, 12, 177-208.
15. Barnes R., Rosenfeld R., Burstein S. i wsp. Pituitary ovarian responses to nafarelin testing in the polycystic ovary syndrome. N. Engl. J. Med., 1989, 320, 559-565.
16. Dunaif A., Scott D., Finegood D. i wsp. The isnulin sensitizing agent troglitazone: a novel therapy for the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1996, 81, 3299-3306.
17. Dunaif A., Xia J., Book C. i wsp. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle, a potential mechanism for insulin resistance in the polycystic ovary syndrome. J. Clin. Invest., 1995, 96, 801-810.
18. Moller D.E., Flier J.S. Insulin resistance: Mechanism, syndromes and implications. N. Engl. J. Med., 1991, 325, 938-948.
19. Marsden P.J., Murdoch A.P., Taylor R. Tissue insulin sensitivity and body wieght in polycystic ovary syndrome. Clin. Endocrinol., 2001, 55, 191-199.
20. Dunaif A., Segal K.R., Shelley D.R. i wsp. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes, 1992, 41, 1257-1266.
21. Rosenbaum D., Haber R.S., Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT4 glucose transporters in adipocytes. Am. J. Physiol., 1993, 264, E197-E202.
22. Bergman R.N., Phillips L.S., Cobelli C. Physiologic evaluation of facors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J. Clin. Invest., 1981, 68, 1456-1467.
23. Ehrmann D.A., Sturis J., Byrne M.M. i wsp. Insulin Secretory Defects in Polycystic Ovary Syndrome. J. Clin. Invest., 1995, 96, 520-527.
24. Dunaif A., Finegoog D.T. Beta-cell Dysfunction Independent of Obesity and Glucose Intolerance in the Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab., 1996, 81, 942-947.
25. Franks S. Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol., 1989, 31, 87-120.
26. Morales A.J., Laughlin G.A., Butzow T i wsp. Insulin, somatotropic and luteinising hormone axis in lean and obese women with polycystic ovarian syndrome: common and distinct features. J. Clin. Endocrinol. Metab., 1996, 81, 2854-2864.
27. Dahlgren E., Janson P.O., Johansson S. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta. Obstet. Gynecol. Scand., 1992, 71, 599-604.
28. Ehrmann D.A., Barnes R.B., Rosenfeld R.L. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 1999, 22, 141-146.
29. Legro R.S., Kunselman A.R., Dodson W.C. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab., 1999, 84, 165-169.
30. Elting M.W., Korsen T.J.M., Bezemer P.D. i wsp. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow up study of Dutch PCOS population. Hum. Reprod., 2001, 16, 556-560.
31. Dahlgren E., Johansson S., Lindstedt G. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natoral history and circulating hormones. Fertil. Steril., 1992, 57, 505-513.
32. Holte J., Gennarelli G., Wide L. i wsp. High Prevalence of polycystic Ovaries and Associated Clinical, Endocrine and Metabolic Features in women with Previous Gestational Diabetes Mellitus. J. Clin. Endocrinol. Metab., 1997, 83, 1143-1150.
33. Zimmermann S., Pfillips R.A., Dunaif A. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J. Clin. Endocrinol. Metab., 1992, 75, 508-513.
34. Sampson M., Kong C., Patel A. i wsp. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin. Endocrinol., 1996, 45, 623-629.
35. Talbott E.O., Guzick D.S., Sutton K. i wsp. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle aged women. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2414-2421.
36. Birdsaall M.A., Farquar C.M. Polycystic ovaries in pre and postmenopausal women. Clin. Endocrinol., 1996, 44, 269-276.
37. Pierpoint T., McKeigue P.M., Isaacs A.J. i wsp. Mortality of women with polycystic ovary syndrome at long term follow up. J. Clin. Epidem., 1998, 51, 581-588.
38. Wild S., Pierpoint T., McKeigue P. i wsp. Cardiovascular disease in women with polycystic ovary syndrome at long term follow up: A retrospective cohort study. Clin. Endocrinol., 2000, 52, 595-600.
39. Wild S., Pierpoint T., Jacobs H. i wsp. Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow up study. Hum. Fertil., 2000, 3, 101-105.
40. Kiddy D.S., Hamilton F.D., Bush A. i wsp. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. Oxf., 1992, 36, 105-111.
41. Velasquez E.M, Mendoza S., Hamer T. i wsp. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenemia and systolic blood pressure ahilee facilitating normal menses and pregnancy. Metabolism, 1994, 43, 647-654.
42. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med., 1996, 335, 617-623.